Search results for: hospital

Study Finds Mirikizumab Superior to Secukinumab for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP | August 7, 2020

In a comparison study, subcutaneous mirikizumab proved superior to subcutaneous in achieving skin clearance in patients with plaque psoriasis…

ACR Convergence 2020 Keynote Speaker to Discuss COVID-19 & a Changing Medical Communications Industry

Catherine Kolonko | August 6, 2020

Editor’s note: Registration for ACR Convergence 2020 is now open. Less than a year after becoming editor in chief of The New England Journal of Medicine (NEJM), Eric Rubin, MD, PhD, found himself in the thick of the COVID-19 pandemic. SARS-CoV-2-related submissions flooded the journal office at an unprecedented pace, making an impact on the…

Guselkumab Approved for PsA

Michele B. Kaufman, PharmD, BCGP | August 6, 2020

Based on data from two clinical trials, the FDA has approved guselkumab to treat adult patients with active psoriatic arthritis…

ACR Convergence 2020: Reimagining the ACR/ARP Annual Meeting

Ellen M. Gravallese, MD | August 5, 2020

Looking back on last year’s ACR/ARP annual meeting, I recall the energy and excitement of attendees as they participated in sessions covering the latest scientific concepts and new directions in our field. In 2019, we piloted a number of innovative ways to modernize and enhance future ACR meetings, with the promise of delivering a transformed…

FDA Approves Secukinumab for Non-Radiographic Axial Spondyloarthritis

Michele B. Kaufman, PharmD, BCGP | August 5, 2020

In June, the FDA approved secukinumab to treat non-radiographic axial spondyloarthritis after data from a clinical trial demonstrated its efficacy…

Telemedicine Highlights Health Disparities During Pandemic

Carolyn Crist | August 4, 2020

NEW YORK (Reuters Health)—The COVID-19 pandemic has accelerated the expansion of telemedicine across the U.S., which has opened up access to doctor’s offices for families with limited resources. But at the same time, the health disparity gap could continue to widen unless safeguards are put into place, according to a pair of new editorials. “There…

IL-1-Beta Blockade May Slow OA Progression

Reuters Staff | August 4, 2020

NEW YORK (Reuters Health)—Interleukin (IL) 1 beta is a key player in the osteoarthritis (OA) inflammatory process and inhibiting it may help slow the disease process, according to an exploratory analysis of data from the CANTOS trial.1 CANTOS participants who were treated with the IL-1-beta inhibitor canakinumab had a significantly lower rate of total hip…

Study Compares Ixekizumab with Ustekinumab for the Treatment of Nail Psoriasis

Michele B. Kaufman, PharmD, BCGP | August 4, 2020

In a head-to-head study, ixekizumab was a more effective treatment for nail psoriasis than ustekinumab and resulted in greater skin clearance for patients with plaque psoriasis…

Tocilizumab Fails Late-Stage Trial for COVID-19

John Revill | July 29, 2020

ZURICH (Reuters)—Roche’s attempt to retool its rheumatoid arthritis drug Actemra/RoActemra (tocilizumab) to treat patients hospitalized with severe COVID-19-related pneumonia has failed in a late-stage trial, the Swiss company said on July 29. Roche launched the 452-patient trial in March as it joined other pharmaceutical companies seeking to re-purpose existing medicines to fight the pandemic. The…

Denosumab Dosing Delays Tied to Increased Fracture Risk

Megan Brooks | July 27, 2020

NEW YORK (Reuters Health)—Denosumab injection delays of more than four months are associated with an increased risk of fracture compared with on-time injections, especially at the spine, new research indicates. “This study suggests the importance of timely denosumab administration when used for long-term osteoporosis management,” the researchers write in Annals of Internal Medicine.1 “When starting…